"Eflornithine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
| Descriptor ID |
D000518
|
| MeSH Number(s) |
D12.125.068.665.340 D12.125.095.765.340
|
| Concept/Terms |
Eflornithine- Eflornithine
- alpha-Difluoromethyl Ornithine
- Ornithine, alpha-Difluoromethyl
- alpha Difluoromethyl Ornithine
- alpha-Difluoromethylornithine
- alpha Difluoromethylornithine
Eflornithine Hydrochloride- Eflornithine Hydrochloride
- Hydrochloride, Eflornithine
- Eflornithine Monohydrochloride, Monohydrate
- Monohydrochloride, Monohydrate Eflornithine
|
Below are MeSH descriptors whose meaning is more general than "Eflornithine".
Below are MeSH descriptors whose meaning is more specific than "Eflornithine".
This graph shows the total number of publications written about "Eflornithine" by people in this website by year, and whether "Eflornithine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Eflornithine" by people in Profiles.
-
Improvement of dermatological symptoms in patients with Bachmann-Bupp syndrome using difluoromethylornithine treatment. Pediatr Dermatol. 2023 May-Jun; 40(3):528-531.
-
Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol. 2007 Jan; 46(1):94-8.
-
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006 Aug; 176(2):500-4.
-
The chemopreventive agents 4-HPR and DFMO inhibit growth and induce apoptosis in uterine leiomyomas. Am J Obstet Gynecol. 2004 Mar; 190(3):686-92.
-
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis. 2003 May; 24(5):945-52.
-
Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis. 2002 Dec; 23(12):2095-102.
-
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000 Oct; 6(10):3878-84.
-
Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A. 2000 Mar 28; 97(7):3461-6.
-
Response and progression in recurrent malignant glioma. Neuro Oncol. 1999 10; 1(4):282-8.
-
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis. 1999 Mar; 20(3):425-30.